由Sintilimab诱导的有毒表皮解:一个案例报告
Ya-Lei Lye1, Bin Shan2, Chen-Hong Jia3
1Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Annals of dermatology
|October 19, 2023
概括
作为一种免疫检查点抑制剂,辛提利马布可以在癌症患者中引起严重的皮肤反应,例如有毒表皮解. 及时检测和用葡萄糖皮质类固醇治疗对于管理这些不良事件至关重要.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 辛提利马布是一种用于癌症治疗的抗编程细胞死亡受体-1抗体.
- 免疫检查点抑制剂 (ICI) 与皮肤反应有关,尽管严重事件很少发生.
- 与化疗相结合的sintilimab的安全性在晚期状非小细胞肺癌中得到证实.
研究的目的:
- 报告一种罕见的与sintilimab治疗相关的有毒表皮解 (TEN) 病例.
- 强调识别和管理ICI引起的严重皮肤不良事件的重要性.
主要方法:
- 一个用sintilimab治疗的老年瘤患者的案例研究.
- 使用药物因果关系算法进行表皮解和FDA定性分析的因果评估.
- 治疗包括高剂量的葡萄糖皮质类固醇,支持性护理和局部伤口治疗.
主要成果:
- 患者在免疫疗法开始后三周出现了广泛的皮疹,,斑点,水泡,泡和侵蚀.
- 患者对高剂量葡萄糖皮质类固醇和支持性治疗产生了积极反应.
- 确定不良事件与sintilimab治疗有关.
结论:
- 毒性表皮解是一种罕见但严重的不良事件,与sintilimab相关.
- 与ICI相关的不良反应的及时识别和管理对于患者的安全至关重要.
- 对于ICI的临床应用,必须严格遵守基于证据的研究.
更多相关视频
相关概念视频
Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...


